- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03789578
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
September 28, 2021 updated by: Novo Nordisk A/S
A Trial to Investigate Single Dose Pharmacokinetics of NNC0148-0287sema in a Fixed Ratio Compared With Insulin 287 and Semaglutide Given Separately in Subjects With Type 2 Diabetes
The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together.
This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when given alone or together.
Participants will get 3 study medicines at 3 different time points: 1) a combination of semaglutide plus insulin 287, 2) insulin 287 alone and 3) semaglutide alone.
The order in which participants get them is decided by chance.
Participants will get all medicines as an injection under the skin in the thigh.
The injections will be done by study staff.
The time between injections is 6 to 9 weeks.
The study will last for about 19 to 32 weeks in total.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Neuss, Germany, 41460
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 64 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent
- Diagnosed with type 2 diabetes mellitus more than or equal to 180 days prior to the day of screening
- Body weight between 80.0 to 120.0 kg (both inclusive)
- Glycosylated haemoglobin (HbA1c) 6.0 to 8.5% (both inclusive)
- No current and no regular previous intake of insulin. Previous insulin treatment for short periods of time (a maximum of 14 days) is allowed, as well as insulin use during a previous period of gestational diabetes in the past (as declared by the subject or reported in the medical records)
- Stable daily dose(s) of the following anti-diabetic drug(s)/regimen within the past 90 days prior to the day of screening: a) Any metformin formulation (dose as documented in the subject medical record), b) One other oral antidiabetic drug (dose as documented in the subject medical record) is allowed, but not mandatory: Insulin secretagogue (sulphonylureas), dipeptidyl peptidase 4 (DPP-4) inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor
Exclusion Criteria:
- Known or suspected hypersensitivity to trial products or related products
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
- Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
- Receipt of any investigational medicinal product within 90 days before screening
- History of severe allergies to drugs or foods or a history of severe anaphylactic reaction
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Semaglutide plus insulin 287
Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
|
Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
|
Experimental: Semaglutide alone
Participants will get a single dose of semaglutide (treatment B) alone.
|
Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
Other Names:
|
Experimental: Insulin 287 alone
Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
|
Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCI287,0-∞ area under the serum insulin 287 concentration-time curve from 0 hours to infinity after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
Cmax, I287, maximum observed serum insulin 287 concentration after a single dose
Time Frame: 0-840 hours
|
Measured in pmol/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
tmax, I287, time to maximum observed serum insulin 287 concentration after a single dose
Time Frame: 0-840 hours
|
Measured in hour (h) for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
|
0-840 hours
|
AUCSema,0-∞, area under the plasma semaglutide concentration-time curve from 0 hours to infinity after a single dose
Time Frame: 0-840 hours
|
Measured in pmol*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
Cmax,Sema, maximum observed plasma semaglutide concentration after a single dose
Time Frame: 0-840 hours
|
Measured in pmol/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
tmax,Sema, time to maximum observed plasma semaglutide concentration after a single dose
Time Frame: 0-840 hours
|
Measured in hour (h) for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
|
0-840 hours
|
Number of treatment emergent adverse events
Time Frame: Day 1 (beginning of each period) to day 36 (end of each period)
|
Count of events.
|
Day 1 (beginning of each period) to day 36 (end of each period)
|
Number of hypoglycaemic episodes
Time Frame: Day 1 (beginning of each period) to day 36 (end of each period)
|
Count of episodes.
|
Day 1 (beginning of each period) to day 36 (end of each period)
|
Antibodies for insulin 287: Change in anti-insulin 287 binding antibody levels
Time Frame: Day -1 (pre-dose), Day 36 (end of period)
|
Measured as percentage B/T following administration of NNC0148 -0287sema and insulin 287.
|
Day -1 (pre-dose), Day 36 (end of period)
|
Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.
|
Day 36 (end of period)
|
Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.
|
Day 36 (end of period)
|
Antibodies for semaglutide: Change in anti-semaglutide binding antibody levels
Time Frame: Day -1 (pre-dose), Day 36 (end of period)
|
Measured as percentage B/T following administration of NNC0148 -0287sema
|
Day -1 (pre-dose), Day 36 (end of period)
|
Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema.
|
Day 36 (end of period)
|
Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous glucagon-like peptide-1 (GLP-1)
Time Frame: Day 36 (end of period)
|
Percentage of events (yes/no) following administration of NNC0148 -0287sema.
|
Day 36 (end of period)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-semaglutide binding antibody levels
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Measured as percentage B/T.
|
Day 151 (follow-up/end-of-trial visit)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous GLP-1
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-insulin 287 binding antibody levels
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Measured as percentage B/T.
|
Day 151 (follow-up/end-of-trial visit)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1
Time Frame: Day 151 (follow-up/end-of-trial visit)
|
Percentage of events (yes/no).
|
Day 151 (follow-up/end-of-trial visit)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 17, 2019
Primary Completion (Actual)
October 10, 2019
Study Completion (Actual)
October 10, 2019
Study Registration Dates
First Submitted
December 27, 2018
First Submitted That Met QC Criteria
December 27, 2018
First Posted (Actual)
December 28, 2018
Study Record Updates
Last Update Posted (Actual)
September 29, 2021
Last Update Submitted That Met QC Criteria
September 28, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1535-4359
- U1111-1204-8233 (Other Identifier: World Health Organization (WHO))
- 2017-004538-27 (Registry Identifier: European Medicines Agency (EudraCT))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting